6 days Ago By ABMN Staff
Alliancebernstein L.P. trimmed its stake in Inari Medical, Inc.
( NASDAQ:NARI – Free Report ) by 97.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 64,142 shares of the company’s stock after selling 2,082,878 shares during the period.
Alliancebernstein L.P.’s holdings in Inari Medical were worth $3,274,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in shares of Inari Medical by 0.
5% in the fourth quarter. Vanguard Group Inc. now owns 5,628,875 shares of the company’s stock valued at $287,354,000 after purchasing an additional 30,702 shares during the period.
Jennison Associates LLC grew its position in shares of Inari Medical by 11.8% during the 4th quarter. Jennison Associates LLC now owns 1,763,258 shares of the company’s stock worth $90,014,000 after buying an additional 186,617 shares in the last quarter.
American Century Companies Inc. raised its holdings in shares of Inari Medical by 9.1% in the fourth quarter.
American Century Companies Inc. now owns 1,068,487 shares of the company’s stock valued at $54,546,000 after acquiring an additional 89,108 shares in the last quarter. Charles Schwab Investment Management Inc.
raised its holdings in shares of Inari Medical by 2.6% in the fourth quarter. Charles Schwab Investment Management Inc.
now owns 465,962 shares of the company’s stock valued at $23,787,000 after acquiring an additional 11,990 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its stake in Inari Medical by 5.
2% in the fourth quarter. Principal Financial Group Inc. now owns 308,903 shares of the company’s stock worth $15,769,000 after acquiring an additional 15,368 shares during the period.
90.98% of the stock is currently owned by institutional investors. Analysts Set New Price Targets Several equities research analysts have recently commented on NARI shares.
Baird R W lowered shares of Inari Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 7th. Robert W. Baird reissued a “neutral” rating and issued a $80.
00 price objective (down previously from $81.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Piper Sandler increased their target price on Inari Medical from $52.
00 to $80.00 and gave the company a “neutral” rating in a research report on Tuesday, January 7th. William Blair restated a “market perform” rating on shares of Inari Medical in a research note on Tuesday, January 7th.
Finally, Canaccord Genuity Group reaffirmed a “hold” rating and set a $80.00 price objective (up previously from $74.00) on shares of Inari Medical in a research report on Tuesday, January 7th.
Twelve investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $68.00.
Inari Medical Stock Performance Shares of Inari Medical stock opened at $79.97 on Tuesday. The firm’s 50 day simple moving average is $79.
96 and its two-hundred day simple moving average is $64.73. The firm has a market capitalization of $4.
68 billion, a price-to-earnings ratio of -59.24 and a beta of 1.02.
Inari Medical, Inc. has a 12-month low of $36.73 and a 12-month high of $79.
99. Inari Medical Company Profile ( Free Report ) Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.
Read More Want to see what other hedge funds are holding NARI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inari Medical, Inc. ( NASDAQ:NARI – Free Report ).
Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter ..
